Skip to main content
SpringerLink
Log in

Secondary Prevention after Ischemic Strokes due to Hypercoagulable States

  • Chapter
Book cover Ischemic Stroke Therapeutics

  • 2143 Accesses

Abstract

Hypercoagulable states are the presumed contributor of about 4 % of all ischemic strokes. While the prevalence of a hypercoagulable predisposition among stroke patients is relatively low (vs. other pathophysiologic mechanisms), and the association of hypercoagulable states with stroke risk is comparatively weak (vs. other risk factors), fortunately identifying patients with a likelihood of hypercoagulability as the underlying stroke mechanism is not generally difficult since these patients tend to be younger with few or no vascular risk factors, have a history of recurrent thromboembolic events, have a family history of thromboembolic events, or present with an index stroke not readily linked to commonly encountered causes. However, testing for hypercoagulability is of low yield in the general stroke population and the impact of treatment on stroke recurrence is not well established. This chapter describes prothrombotic disorders commonly associated with ischemic stroke and presents a rational approach to the management of stroke patients with a known or suspected hypercoagulable tendency.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hart RG, Kanter MC. Hematologic disorders and ischemic stroke. A selective review. Stroke. 1990;21(8):1111–21.

    Article  CAS  PubMed  Google Scholar 

  2. Brey RL, Hart RG, Sherman DG, Tegeler CH. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology. 1990;40(8):1190–6.

    Article  CAS  PubMed  Google Scholar 

  3. Janardhan V, Wolf PA, Kase CS, Massaro JM, D’Agostino RB, Franzblau C, et al. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. Stroke. 2004;35(3):736–41.

    Article  PubMed  Google Scholar 

  4. Pezzini A, Del Zotto E, Magoni M, Costa A, Archetti S, Grassi M, et al. Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale. Stroke. 2003;34(1):28–33.

    Article  PubMed  Google Scholar 

  5. Bushnell C, Goldstein LB. Screening for hypercoagulable syndromes following stroke. Curr Atheroscler Rep. 2003;5(4):291–8.

    Article  PubMed  Google Scholar 

  6. Fields MC, Levine SR. Thrombophilias and stroke: diagnosis, treatment, and prognosis. J Thromb Thrombolysis. 2005;20(2):113–26.

    Article  PubMed  Google Scholar 

  7. Marlar RA, Mastovich S. Hereditary protein C deficiency: a review of the genetics, clinical presentation, diagnosis and treatment. Blood Coagul Fibrinolysis. 1990;1(3):319–30.

    Article  CAS  PubMed  Google Scholar 

  8. Rappaport ES, Speights VO, Helbert B, Trowbridge A, Koops B, Montgomery RR, et al. Protein C deficiency. South Med J. 1987;80(2):240–2.

    Article  CAS  PubMed  Google Scholar 

  9. Morris JG, Singh S, Fisher M. Testing for inherited thrombophilias in arterial stroke: can it cause more harm than good? Stroke. 2010;41(12):2985–90.

    Article  PubMed  Google Scholar 

  10. Kutteh WH, Triplett DA. Thrombophilias and recurrent pregnancy loss. Semin Reprod Med. 2006;24(1):54–66.

    Article  CAS  PubMed  Google Scholar 

  11. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet. 2003;361(9361):901–8.

    Article  PubMed  Google Scholar 

  12. Wu O, Robertson L, Twaddle S, Lowe GD, Clark P, Greaves M, et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess. 2006;10(11):1–110.

    Article  CAS  PubMed  Google Scholar 

  13. Ortiz G, Koch S, Romano JG, Forteza AM, Rabinstein AA. Mechanisms of ischemic stroke in HIV-infected patients. Neurology. 2007;68(16):1257–61.

    Article  CAS  PubMed  Google Scholar 

  14. Mochan A, Modi M, Modi G. Protein S deficiency in HIV associated ischaemic stroke: an epiphenomenon of HIV infection. J Neurol Neurosurg Psychiatry. 2005;76(10):1455–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Qureshi AI. HIV infection and stroke: if not protein S deficiency then what explains the relationship? J Neurol Neurosurg Psychiatry. 2005;76(10):1331.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Said JM, Ignjatovic V, Monagle PT, Walker SP, Higgins JR, Brennecke SP. Altered reference ranges for protein C and protein S during early pregnancy: implications for the diagnosis of protein C and protein S deficiency during pregnancy. Thromb Haemost. 2010;103(5):984–8.

    Article  CAS  PubMed  Google Scholar 

  17. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA. 1997;277(16):1305–7.

    Article  CAS  PubMed  Google Scholar 

  18. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85(6):1504–8.

    CAS  PubMed  Google Scholar 

  19. Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood. 1994;84(4):1031–5.

    CAS  PubMed  Google Scholar 

  20. Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. 1998;79(4):706–8.

    CAS  PubMed  Google Scholar 

  21. Rosendaal FR, Vos HL, Poort SL, Bertina RM. Prothrombin 20210A variant and age at thrombosis. Thromb Haemost. 1998;79(2):444.

    CAS  PubMed  Google Scholar 

  22. Blajchman MA. An overview of the mechanism of action of antithrombin and its inherited deficiency states. Blood Coagul Fibrinolysis. 1994;5 Suppl 1:S5–11. discussion S59–64.

    Article  CAS  PubMed  Google Scholar 

  23. Corral J, Hernandez-Espinosa D, Soria JM, Gonzalez-Conejero R, Ordonez A, Gonzalez-Porras JR, et al. Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood. 2007;109(10):4258–63.

    Article  CAS  PubMed  Google Scholar 

  24. Picard V, Nowak-Gottl U, Biron-Andreani C, Fouassier M, Frere C, Goualt-Heilman M, et al. Molecular bases of antithrombin deficiency: twenty-two novel mutations in the antithrombin gene. Hum Mutat. 2006;27(6):600.

    Article  PubMed  Google Scholar 

  25. Wilson WA, Gharavi AE. Hypercoagulable states. Ann Intern Med. 1997;127(12):1128. author reply 9.

    Article  CAS  PubMed  Google Scholar 

  26. Triplett DA. Antiphospholipid antibodies. Arch Pathol Lab Med. 2002;126(11):1424–9.

    CAS  PubMed  Google Scholar 

  27. Exner T, Sahman N, Trudinger B. Separation of anticardiolipin antibodies from lupus anticoagulant on a phospholipid-coated polystyrene column. Biochem Biophys Res Commun. 1988;155(2):1001–7.

    Article  CAS  PubMed  Google Scholar 

  28. McNeil HP, Chesterman CN, Krilis SA. Binding specificity of lupus anticoagulants and anticardiolipin antibodies. Thromb Res. 1988;52(6):609–19.

    Article  CAS  PubMed  Google Scholar 

  29. McNeil HP, Chesterman CN, Krilis SA. Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics. Br J Haematol. 1989;73(4):506–13.

    Article  CAS  PubMed  Google Scholar 

  30. Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, Sciacca RR, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291(5):576–84.

    Article  CAS  PubMed  Google Scholar 

  31. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Neurology. 1993;43(10):2069–73.

    Google Scholar 

  32. Brey RL. Antiphospholipid antibodies in young adults with stroke. J Thromb Thrombolysis. 2005;20(2):105–12.

    Article  CAS  PubMed  Google Scholar 

  33. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med. 1990;112(9):682–98.

    Article  CAS  PubMed  Google Scholar 

  34. Bushnell CD, Goldstein LB. Diagnostic testing for coagulopathies in patients with ischemic stroke. Stroke. 2000;31(12):3067–78.

    Article  CAS  PubMed  Google Scholar 

  35. Bushnell CD, Goldstein LB. Homocysteine testing in patients with acute ischemic stroke. Neurology. 2002;59(10):1541–6.

    Article  CAS  PubMed  Google Scholar 

  36. Choi BO, Kim NK, Kim SH, Kang MS, Lee S, Ahn JY, et al. Homozygous C677T mutation in the MTHFR gene as an independent risk factor for multiple small-artery occlusions. Thromb Res. 2003;111(1-2):39–44.

    Article  CAS  PubMed  Google Scholar 

  37. Sazci A, Ergul E, Tuncer N, Akpinar G, Kara I. Methylenetetrahydrofolate reductase gene polymorphisms are associated with ischemic and hemorrhagic stroke: dual effect of MTHFR polymorphisms C677T and A1298C. Brain Res Bull. 2006;71(1-3):45–50.

    Article  CAS  PubMed  Google Scholar 

  38. Kristensen B, Malm J, Nilsson TK, Hultdin J, Carlberg B, Dahlen G, et al. Hyperhomocysteinemia and hypofibrinolysis in young adults with ischemic stroke. Stroke. 1999;30(5):974–80.

    Article  CAS  PubMed  Google Scholar 

  39. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291(5):565–75.

    Article  CAS  PubMed  Google Scholar 

  40. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354(15):1567–77.

    Article  CAS  PubMed  Google Scholar 

  41. Bushnell CD, Siddiqi Z, Goldstein LB. Improving patient selection for coagulopathy testing in the setting of acute ischemic stroke. Neurology. 2001;57(7):1333–5.

    Article  CAS  PubMed  Google Scholar 

  42. Bushnell C, Siddiqi Z, Morgenlander JC, Goldstein LB. Use of specialized coagulation testing in the evaluation of patients with acute ischemic stroke. Neurology. 2001;56(5):624–7.

    Article  CAS  PubMed  Google Scholar 

  43. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Texas Tech University Health Sciences Center at El Paso, 4800 Alberta Ave, El Paso, TX, 79905, USA

    Salvador Cruz-Flores M.D., M.P.H.

Authors
  1. Salvador Cruz-Flores M.D., M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Salvador Cruz-Flores M.D., M.P.H. .

Editor information

Editors and Affiliations

  1. Admiral Pihl Professor and Chairman of Neurology, Medical University of South Carolina, Charleston, South Carolina, USA

    Bruce Ovbiagele

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Cruz-Flores, S. (2016). Secondary Prevention after Ischemic Strokes due to Hypercoagulable States. In: Ovbiagele, B. (eds) Ischemic Stroke Therapeutics. Springer, Cham. https://doi.org/10.1007/978-3-319-17750-2_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-17750-2_17

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-17749-6

  • Online ISBN: 978-3-319-17750-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation